RYH0 Stock Overview
A clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sareum Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.30 |
| 52 Week High | UK£0.69 |
| 52 Week Low | UK£0.11 |
| Beta | -0.96 |
| 1 Month Change | 11.11% |
| 3 Month Change | 11.11% |
| 1 Year Change | -51.22% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| RYH0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.7% | -2.2% | -2.0% |
| 1Y | -51.2% | -15.8% | 6.8% |
Return vs Industry: RYH0 underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: RYH0 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| RYH0 volatility | |
|---|---|
| RYH0 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RYH0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RYH0's weekly volatility has decreased from 18% to 7% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5 | n/a | www.sareum.com |
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc Fundamentals Summary
| RYH0 fundamental statistics | |
|---|---|
| Market cap | €40.57m |
| Earnings (TTM) | -€4.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.8x
P/E RatioIs RYH0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RYH0 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£3.42m |
| Earnings | -UK£3.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.027 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RYH0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 19:26 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sareum Holdings plc is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Hall | Hardman & Co. |
| Yi-Ling Liu | Hybridan LLP |
| Miles Dixon | Peel Hunt LLP |